On Monday, Actinium Pharmaceuticals Inc (NYSEMKT:ATNM)’s shares declined -8.20% to $2.80.
Investors sometimes forget that companies go public to take advantage of capital markets in order to fund operations and push forward for new development. There’s always potential for dilutive effects to take hold however, the right kind of funding from the right groups can bode well for both the small cap companies and their shareholders. Several stock which have demonstrated that funding can equal positive momentum this year have comprised of Enviro-Serv Inc. (EVSV), Actinium Pharmaceuticals, Inc. (NYSE MKT: ATNM), and Fortress Biotech, Inc. (FBIO).
Recently, Enviro-Serv declared that it had obtained the proper funding to firm up its agreement with Pestmaster Services, a national Franchisor with 30 locations and a dominant player not only in general pest control but also in the Government contracts sector for pest administration. Chris Trina, CEO of Enviro-Serv stated he has aggressive plans to bid on some of the largest Government pest control contracts in the country. This added business model according to the CEO, could result in an enhance in compriseent revenue and the Company also stated that it anticipates 2015 to be the busiest year in its history. Since the startning of May, shares of EVSV have raised from levels hovering between .0001-.0002 to highs earlier this week of $0.0015 as anticipation continues to grow for the final closing on the Pestmaster agreement “on or before June 30, 2015.”
Actinium Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs for the treatment of cancer. The company develops therapies for life threatening diseases using its alpha particle immunotherapy platform and other related and similar technologies. Its products comprise Actimab-A, an antibody-drug construct, which comprises monoclonal antibody Lintuzumab and alpha emitting radioisotope actinium 225; and is in multicenter Phase I/II clinical trials for acute myeloid leukemia (AML).
AstraZeneca plc (ADR) (NYSE:AZN)’s shares gained 0.75% to $67.20.
AstraZeneca plc (ADR) (AZN) presented at the European League Against Rheumatism Annual Congress (EULAR 2015) in Rome, results of its Phase III double-blind, multicenter, placebo-controlled trial CRYSTAL, investigating the potential of lesinurad, a selective uric acid re-absorption inhibitor (SURI), when used in combination with the xanthine oxidase inhibitor (XOI) febuxostat. The results demonstrated that lesinurad in combination with febuxostat lowered serum uric acid (sUA) levels and reduced tophus area to a greater extent than febuxostat alone. Lesinurad is an investigational agent that inhibits the uric acid transporter URAT1 in the kidney, increasing uric acid excretion and thereby lowering sUA. Lesinurad works in combination with febuxostat to provide a dual mechanism of action which enhances excretion and decreases production of uric acid.
AstraZeneca PLC engages in the discovery, development, and commercialization of prescription medicines for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection, and neuroscience diseases worldwide. Its principal products comprise Crestor for the treatment of dyslipidaemia and hypercholesterolemia; Seloken/Toprol-XL to control hypertension, and heart failure and angina; Onglyza for diabetes mellitus; Iressa for non-small cell lung cancer; Faslodex for breast cancer in post-menopausal women; and Zoladex for prostate cancer, breast cancer, and certain benign gynaecological disorders.
At the end of Mondays trade, Himax Technologies, Inc. (ADR) (NASDAQ:HIMX)‘s shares dipped -1.17% to $8.48.
Himax Technologies, Inc. (HIMX) (“Himax” or “Company”), a leading supplier and fabless manufacturer of display drivers and other semiconductor products, declares that the Company will attend the 2nd Annual Morgan Stanley Global Emerging Markets “GEMs” conference, which will be held in New York City on July 8-9, 2015.
The Company will host one-on-one meetings with investors during the event dates. Conference participation is by invitation only and registration is mandatory. For more information on the conference or to plan a one-on-one meeting with Himax’s administration, please contact your Morgan Stanley representative.
Himax Technologies, Inc., a fabless semiconductor company, provides display imaging processing technologies to consumer electronics worldwide. The company operates through Driver IC and Non-Driver Products segments. It offers display driver integrated circuits (ICs) and timing controllers used in televisions (TVs), laptops, monitors, mobile phones, tablets, digital cameras, car navigation, and other consumer electronics devices.
Galena Biopharma Inc (NASDAQ:GALE), ended its Monday’s trading session with 2.82% gain, and closed at $1.82.
Galena Biopharma, Inc. (GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology therapeutics that address major medical needs across the full spectrum of cancer care, recently declared that data from the Company’s Phase 2 clinical trial of GALE-401 was presented at the European Hematology Association 20th Congress in Vienna, Austria. The GALE-401 Phase 2 pilot study is a single arm, open label, multi-center study evaluating the efficacy and safety of anagrelide controlled release in subjects with thrombocytosis secondary to essential thrombocythemia (ET) and other myeloproliferative neoplasms (MPNs).
The poster presentation, entitled, “Phase 2 Study of a Novel Controlled-Release Formulation of Anagrelide (GALE-401) in Subjects with Myeloproliferative Neoplasm (MPN)-Related Thrombocytosis,” was presented on Saturday, June 13, 2015. The Phase 2 study demonstrated that GALE-401 was well tolerated with primarily Grade 1 and 2 toxicities in 16 of the 18 subjects enrolled. The efficacy shown in the trial compares favorably to historical anagrelide immediate release (IR) response rates with the following platelet response: overall response rate (ORR) of 78% (14/18); complete response (CR) of 39% (7/18); partial response (PR) of 39% (7/18). The median time to response was 5 weeks (range, 3-10), and the median duration of response has not yet been reached. Based on the data, the investigators concluded that GALE-401 remains a viable potential treatment option for MPNs, and a randomized trial comparing GALE-401 as compared to anagrelide IR is warranted. Final data from the GALE-401 Phase 2 trial is predictable to be presented at the American Society of Hematology conference in December.
Galena Biopharma, Inc., a biopharmaceutical company, focuses on developing and commercializing oncology therapeutics that address major unmet medical needs across cancer care. Its commercial products comprise Abstral, a sublingual tablet that is used for the administration of breakthrough pain in patients with cancer; and Zuplenz, an oral soluble film for use in the prevention of emetogenic chemotherapy-induced, radiotherapy-induced, and post-operative nausea and vomiting.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
